|
 |
EloxatinThis page contains recent news articles, when available, and an overview of Eloxatin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Eloxatin (when available) Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. For the treatment of malignant neoplasm of colon, rectum, and ovary Mechanism Of Action: after activationm it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function. News Articles on Oxaliplatin Sanofi-Aventis, eyeing OTC market, beefs up US presence - Dec 23, 2009 That could prove an important strategy, as many of its prescription drugs come off patent, including cancer drug Eloxatin, heart drug Plavix and ... Medical Marketing and Media Sanofi Pasteur To Cut Pharmaceutical Jobs - Dec 17, 2009 Some of its biggest sellers, from sleeping pill Ambien to the cancer drug Eloxatin, have gone generic, and one of the biggest is yet to come: the ... Pharmaceutical Jobs Sanofi 3Q Pft +6.8%; Ups Target On Swine Flu Vaccine - Oct 30, 2009 Double-digit sales growth of diabetes drug Lantus and blood thinner Lovenox helped offset a steep drop in sales of cancer treatment Eloxatin, which were hit ... Wall Street Journal Teva Pharmaceutical 3Q profit rises 3 percent - Nov 3, 2009 ...to $2.23 billion due to the introduction of a generic version of Ortho Tri-Cyclen birth control and a generic version of the cancer treatment Eloxatin. ... Forbes Hospira profits strong on improved efficiencies, generic drug launch - Oct 27, 2009 The drug, oxaliplatin, is the generic version of Sanofi-Aventis' branded Eloxatin. "Hospira delivered strong results in the third quarter, ... Chicago Tribune Sanofi Taps Biotech Firm to Help Pipeline - Nov 11, 2009 Sanofi recently started facing generic competition in some markets for its big-selling anti-clotting drug Plavix and its cancer drug Eloxatin. New York Times Teva Reports Third Quarter 2009 Results - Nov 2, 2009 Quarterly sales benefited from the launch of generic versions of Ortho Tri-Cyclen® Lo (norgestimate/ethinyl estradiol) and Eloxatin® (oxaliplatin) in the ... Reuters Intl sales excluding Caraco grew 29%: Sun Pharma - Oct 29, 2009 Q: Coming to some of your product launch opportunities on generic version of Eloxatin, have you got approval on that, has Sun Pharma already launched it? ... Moneycontrol.com Hospira to close Rocky Mount plant wing - Oct 28, 2009 Oxaliplatin is a generic version of Sanofi-Aventis' drug Eloxatin. Hospira said sales of non-specialty drugs fell 10 percent to $157.4 million. ... Rocky Mount Telegram Zacks Analyst Blog Highlights: Baker Hughes Inc., BJ Services, Teva ... - Nov 5, 2009 The launch of generic versions of Ortho Tri-Cyclen Lo and Eloxatin and continued strong sales from existing products like generic versions of Adderall XR, ... Reuters Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of ... - Nov 9, 2009 Lotrel®, Protonix® and Eloxatin®, the current economic conditions, competition from brand-name companies that are under increased pressure to counter ... WELT ONLINE Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009 - Oct 30, 2009 Net sales of Eloxatin® in the third quarter were euro 193 million, down 44.3%, reflecting the entry of a number of generics into the US market during August ... Reuters Commercial Insight: Cytotoxic Therapies - Market growth will slow due to ... - Oct 30, 2009 Despite facing patent expiry during the forecast period and guaranteed generic entry, Taxotere and Eloxatin will remain in the top three in 2018, ... PRMinds (press release) Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone - Nov 6, 2009 ...from recently launched generic versions of the birth control pill Ortho Tri-Cyclen and the colorectal chemotherapeutic agent Eloxatin (oxaliplatin) to ... BNET Living Without Blockbusters - Oct 28, 2009 ...the $10 billion heart pill that Sanofi sells with Bristol-Myers Squibb ( BMY - news - people ), and Eloxatin, the company's $2 billion cancer drug. ... Forbes Sanofi-Aventis supera previsiones, apoyada por las vacunas contra la gripe A - Oct 30, 2009 Las de Eloxatin bajaron un 40,6% por la competencia de los genéricos en EEUU, hasta los 193 millones. La demanda de vacunas contra la gripe A benefició ... Bolsamania.com Sanofi-Aventis boekt winstgroei 6,8%; verhoogt outlook - Oct 30, 2009 De omzet van het kankermedicijn Eloxatin nam af met 44%, als gevolg van generieke concurrentie in de Verenigde Staten en Europa. Voor geheel 2009 voorziet ... Financieele Dagblad Teva Pharma第三å£ç›ˆåˆ©å¢žé•¿3% - Nov 3, 2009 Teva的北美业务第三å£è?¥æ”¶å¢žé•¿33%，至22.3亿美元，主è¦?得益于é?¿å•è?¯Ortho Tri-Cyclen和抗癌è?¯Eloxatin的仿制版本的推出。该公å?¸å‡ºå”®çš„其它仿制è?¯åŒ…括é™?压è?¯Lotrel与 ... 新浪网 Europas Börsen entziehen sich positiven Vorgaben - Knapp behauptet - Oct 30, 2009 Ein kleiner Wermutstropfen sei der überraschend starke Umsatzrückgang von "Eloxatin", wo die Generika offensichtlich stärker belastet hätten als vermutet. ... Märkische Allgemeine Citigroup Corp. stuft SANOFI-AVENTIS auf buy - Nov 3, 2009 Eloxatin habe auf Grund eines schärferen generischen Wettbewerbs die Schätzung aber verfehlt. Die Markteinführung von Multaq sehe vielversprechend aus. ... wallstreet-online CONSENSUS Sanofi Net pdg T3 vu à +13%, BPA à +9,6%, CA à +8,5% - Oct 27, 2009 ...+ 2,6% Ambien (inscomnie) 214,9 + 6,9% Vaccins 1.012,5 + 6,9% * La version générique d'Eloxatin est disponible aux Etats-Unis depuis le début août. ... Reuters Sanofi-Aventis sobe previsão de lucro - Nov 2, 2009 ...que suportem o incremento das vendas, à medida que medicamentos mais antigos, como o Plavix® eo Eloxatin®, enfrentam a concorrência dos genéricos. ... RCM Pharma Interview vidéo : le DG de Sanofi-aventis, Chris Viehbacher, commente les ... - Oct 30, 2009 Erosion de Plavix et Eloxatin 4. Premiers pas de Multaq 5. Le point sur le vaccin H1N1 6. Mise à jour de la guidance 2009 7. Programme Transforming 8. ... Reuters Schweingrippe gibt Sanofi neuen Schub - Prognose erhöht - Oct 30, 2009 So spürte Sanofi beispielsweise im dritten Quartal in den USA die Konkurrenz durch Generika bei seinem Krebs-Mittel Eloxatin. ... Reuters Deutschland (Pressemitteilung) Sanofi says Eloxatin helps survival after surgery - Jun 3, 2007 PARIS (Reuters) - Early-stage colon cancer patients treated with Eloxatin-based chemotherapy after their tumor had been removed by surgery survived longer ... Reuters UK Sanofi sues Teva over Eloxatin patent - Jun 20, 2007 NEW YORK, June 20 (Reuters) - Sanofi-Aventis (SASY.PA) has sued Teva Industries Ltd. (TEVA.TA)(TEVA.O) over Teva's plans to sell a generic version of the ... Reuters Bowel cancer drug access to widen - Oct 28, 2005 Draft guidance by NHS drug advisers NICE has recommended a combination treatment, including the drug Eloxatin, should be available for NHS patients. ... BBC News Barr seeks OK of generic form of Sanofi's Eloxatin - Jan 9, 2008 NEW YORK, Jan 9 (Reuters) - Barr Pharmaceuticals Inc BRL.N said on Wednesday it has asked US regulators to approve its generic form of French drugmaker ... Reuters Sanofi-Aventis: Positive results in Phase III study of Eloxatin - Mar 20, 2008 SAN FRANCISCO (Thomson Financial) - Sanofi-Aventis late Thursday said that results from a Phase III study showed that Eloxatin, in combination with a ... Forbes Dabur Pharma plans generic versions of Sanofi's Eloxatin - Jun 23, 2007 New Delhi June 22 Oncology specialist Dabur Pharma and Dabur Oncology plc, its UK subsidiary, said that they have submitted two abbreviated new drug ... Hindu Business Line New Eloxatin(R) (Oxaliplatin for Injection) Research in Colorectal... - Jan 26, 2005 BRIDGEWATER, NJ, Jan. 26 /PRNewswire-FirstCall/ -- The sanofi-aventis Group announced today that important data from four Eloxatin(R) (oxaliplatin for ... RedOrbit Sanofi-Aventis Receives FDA Approval for New ELOXATIN(TM) … - Feb 3, 2005 PARIS, Feb. 3 /PRNewswire-FirstCall/ -- The sanofi-aventis Group announced today that it has received marketing approval from the United States Food and ... RedOrbit Sanofi Shrugs Off Generic Pressure - Feb 12, 2008 The patent on Eloxatin, a chemotherapy drug, also recently expired in Europe, hitting sales. ... Excluding sales of Ambien in the US and Eloxatin in Europe, ... Forbes Evaluating Eloxatin-Based Regimens In Gastrointestinal Cancers … - Jun 8, 2006 Sanofi-aventis announced key results from three studies evaluating Eloxatin(R) (oxaliplatin injection) in various gastrointestinal tumor types (colorectal, ... Medical News Today - Medical News Today (press release) New Eloxatin(R) And Taxotere(R) Data In Several Tumor Types To Be … - Jun 1, 2006 Sanofi-aventis US announced today that key study results from the company's leading chemotherapeutic agents, Eloxatin(R) (oxaliplatin injection) and ... Medical News Today - Medical News Today (press release) Eloxatin regimen improving colon cancer survival - May 16, 2008 By Charles E. Buban. MANILA, Philippines—A diagnosis of cancer today is not necessarily the death sentence it may have been a couple of decades ago. ... Inquirer.net … significant benefit of Eloxatin-based chemotherapy combined with … - Jan 31, 2005 Sanofi-aventis announced preliminary results of two large prospective trials evaluating the safety and efficacy of Eloxatin (oxaliplatin for ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Worries Remain for Sanofi-Aventis - Feb 13, 2007 ...the April patent expiration for the insomnia drug Ambien in the US and generic versions of the colorectal cancer drug Eloxatin in Europe. ... TheStreet.com - TheStreet.com (subscription) Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant … - Feb 28, 2006 A summary of the data presented in this manuscript was selected for poster presentation at the 2005 Annual meeting of the American Society for Clinical ... Nature.com Sanofi to cut 927 jobs in France, most in sales - Oct 2, 2008 ...such as blood thinners Lovenox and Plavix and cancer treatment Eloxatin, are being challenged by drugmakers seeking to sell cheaper copies. ... Reuters UK Sanofi sues Teva over Eloxatin patent - Jun 21, 2007 Sanofi-Aventis has sued Teva Industries over the Israeli company's plans to sell a generic version of the French drugmaker's cancer treatment Eloxatin, ... Ha'aretz This Year's Cancer Debutantes - May 11, 2005 Aside from new targeted genetic medicines, there could be some new data on the effectiveness of old-fashioned chemotherapies such as Taxotere and Eloxatin, ... Forbes Sanofi's new Eloxatin consolidates its strong position - Feb 9, 2005 FDA's approval of Sanofi-Aventis' Eloxatin (oxaliplatin) is unlikely to increase the drug's patient base, but the new formulation should consolidate ... DrugResearcher.com Sanofi-Aventis FY results top consensus; 18 treatments in 2007/8... - Feb 13, 2007 The company said it expects the same rate of increase in 2007 despite the end of patent protection for Ambien in the US and generic competition to Eloxatin ... Forbes Breast Cancer Chemotherapy - Breast Cancer Health Information - NY … - Nov 10, 2008 Platinum-based drugs include oxaliplatin (Eloxatin) and carboplatin (Paraplatin). These drugs may be used in combination regiments for advanced cancer or ... New York Times Bowel cancer drugs backing - Apr 26, 2006 Two chemotherapy treatments - one which includes Eloxatin, and the other, known as Xeloda - are thought to offer a potential cure for those caught soon ... Scotsman Eloxatin IV : User Ratings covering uses, effectiveness, interactions... - Oct 9, 2007 I have been very thankful that this drug has been a part of the regimen to sustain my life. Although no significant change has occured in the cancer, ... WebMD New Eloxatin(R) (oxaliplatin injection) Prescribing Information in... - May 27, 2008 BRIDGEWATER, NJ , May 28 /PRNewswire-FirstCall/ -- Sanofi-aventis US announced today that the US Food and Drug Administration (FDA) approved the ... Genetic Engineering News - Genetic Engineering News (press release) … Marketing Approval for a New Formulation of Eloxatin(R) (Oxaliplati... - Feb 7, 2005 Eloxatin(R) INJECTION is a clear, preservative-free, ready for use solution. ... Eloxatin(R) was developed in association with sanofi-aventis and is ... Free with registration - PR Newswire - AccessMyLibrary.com … Of Six-Year Overall Survival Data In The Eloxatin(R) (oxaliplatin... - Feb 21, 2008 Sanofi-aventis announced that the US Food and Drug Administration (FDA) has accepted for filing and assigned priority review status to a supplemental new ... Lifescience-online Drug May Slow Colon Cancer - Jan 23, 2007 Side effects in the study were due primarily to the Eloxatin-based chemotherapy and included pain, numbness and tingling, lowered resistance to infection, ... CBS News Avastin, Eloxatin Plus Standard Therapy Prolong Colorectal Cancer … - Jan 27, 2005 By Karla Gale. NEW YORK JAN 27, 2005 (Reuters Health) - The addition of bevacizumab (Avastin) and oxaliplatin (Eloxatin) to standard chemotherapy prolongs ... Cancerpage.com In Spite Of Strong Growth to Date, Sales of Eloxatin for Colorectal... - Nov 15, 2006 Research and Markets (http://www.researchandmarkets.com/reports/c45259) has announced the addition of Pipeline/Commercial Insight: Colorectal Cancer ... RedOrbit Sanofi's Eloxatin Gets Labeling Update - May 30, 2008 The FDA has approved a labeling change to sanofi-aventis' Eloxatin, an intravenous colon cancer treatment. In the sNDA, which was given priority review, ... FDA news - FDA news (subscription) Benefit of Eloxatin chemo plus Avastin.(PRODUCT DEVELOPMENT)( … - Feb 7, 2005 French drugmaker Sanofi-Aventis has reported encouraging preliminary results from two large prospective trials investigating the safety and efficacy of ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Press Release: New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection)... - Aug 27, 2007 New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Studies Evaluating Eloxatin-Based Regimens in … - Jun 6, 2006 Studies Evaluating Eloxatin-Based Regimens in Gastrointestinal Cancers Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology ... Pay-Per-View - PR Newswire - HighBeam Research Surviving colon cancer - Apr 18, 2008 Sanofi-Aventis, which manufactures Eloxatin, reported that Folfox4 (combination of Eloxatin, leucovorin and fluorouracil) significantly improved overall ... Inquirer.net Colorectal Cancer; Benefit of Eloxatin-based chemo plus bevacizumab... - Mar 5, 2005 2005 MAR 5 - (NewsRx.com & NewsRx.net) -- Sanofi-aventis (SNY) announced preliminary results of 2 large prospective trials evaluating the safety and ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Press Release: Eloxatin(R) (oxaliplatin injection)-Based Chemotherapy... - Jun 4, 2007 Eloxatin(R) (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Perioperative Eloxatin Regimen Reduced Risk Of Relapse In Colorectal ... - Mar 24, 2008 Sanofi-aventis announced that efficacy results of the randomized phase III EORTC 40983 Intergroup study showed that in eligible patients Eloxatin ... emaxhealth.com Press Release: New Eloxatin(R) and Taxotere(R) Data in Several Tumor ... - May 31, 2006 New Eloxatin(R) and Taxotere(R) Data in Several Tumor Types to Be Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO). from ... Pay-Per-View - PR Newswire - HighBeam Research … Significant Benefit of ELOXATIN-Based Chemotherapy Combined With … - Jan 31, 2005 Two Studies Demonstrate Significant Benefit of ELOXATIN-Based Chemotherapy Combined With Bevacizumab in Advanced Colorectal Cancer; Positive Results of ... Pay-Per-View - PR Newswire - HighBeam Research Appeal against Mayne Pharma dropped - Jan 9, 2007 The case related to patents ending for Sanofi Aventis's anti-cancer drug, oxaliplatin, under the brand name Eloxatin, and Mayne Pharma launching its version ... NEWS.com.au Medical News: Therapeutic Radiology - Feb 15, 2006 The drugs were Taxol (paclitaxel), Taxotere (docetaxel), Eloxatin (oxaliplatin), and 5-fluorouracil (5FU). In an accompanying editorial, James H. Doroshow, ... MedPage Today … Cancer; Drug company receives US FDA approval for new Eloxatin … - Mar 8, 2005 Eloxatin injection offers additional convenience to physicians and nurses since it involves fewer steps in the administration of Eloxatin. ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Dabur Pharma Q1 net zooms - Jul 27, 2007 This includes the Para IV filing for oxaliplatin, the generic version of Sanofi-Aventis' registered oncology injectible, Eloxatin. ... Hindu Business Line … Cancer; Drug company receives US FDA approval for new Eloxatin … - Mar 13, 2005 Eloxatin injection offers additional convenience to physicians and nurses since it involves fewer steps in the administration of Eloxatin. ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Good data on Sanofi's Eloxatin and Taxotere at ASCO. - Jun 12, 2006 Good data on Sanofi's Eloxatin and Taxotere at ASCO. French drugmaker Sanofi-Aventis has highlighted strong data on its anticancer drugs Eloxatin ... $9.94 - Pharma Marketletter - Alacra Store ASCO GI: Eloxatin Seen Safe as Add-On to Neoadjuvant Chemoradiation … - Jan 29, 2007 By Ed Susman, Contributing Writer, MedPage Today. ORLANDO, Jan. 29 -- Adding Eloxatin (oxaliplatin) to the pre-operative chemotherapy mix for rectal cancer ... MedPage Today Sanofi-Aventis' Eloxatin Gets FDA Priority Review - Feb 29, 2008 Sanofi-aventis said the FDA has assigned priority review status to its supplemental new drug application (sNDA) for its colorectal cancer drug Eloxatin. ... FDA news - FDA news (subscription) Colorectal Cancer; Data show ELOXATIN-based therapy combined with … - Jan 2, 2005 Patients who received ELOXATIN-based chemotherapy (FOLFOX4) plus bevacizumab (Avastin) showed a statistically significant improvement in overall survival in ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones … and Markets: Cytotoxic Therapies, Camptosar, Eloxatin and Xeloda... - Dec 1, 2006 DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets. com/reports/c46294) has announced the addition of Colorectal Cancer (CRC) ... $4.95 - Business Wire - ECNext Barr Pharmaceuticals confirms Eloxatin injectable patent challenge - Jan 10, 2008 Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Sanofi-Aventis US LLC in ... News-Medical.net New Eloxatin(R) and Taxotere(R) Research to Be Presented at the … - May 10, 2005 PARIS, May 10 /PRNewswire-FirstCall/ -- The sanofi-aventis Group announced today that important results from Eloxatin(R) (oxaliplatin for injection) and ... $4.95 - PR Newswire - ECNext Cancer drugs given OK - Apr 6, 2005 Doctors have fought for three years to give out the drugs ? called Campto and Eloxatin ? on the NHS. They can extend life of advanced bowel cancer patients ... The Sun Update on Advanced Colon Cancer—ASCO 2005 - May 13, 2005 Two studies presented at ASCO 2005 lend support to the comparable efficacy of Xeloda/Eloxatin combinations with intravenous 5-FU/Eloxatin combinations. ... Cancer Consultants International Approvals: Januvia, Synvisc-One, Eloxatin - Jan 29, 2008 January 29, 2008 — The European Commission (EC) has approved sitagliptin tablets for use as add-on therapy to a sulfonylurea both with and without metformin ... Medscape ASCO-GI: Serotonin Receptor Agonist Blocks Neuropathy in Colon … - Jan 30, 2006 ...the 325 patients who were randomized to six months of Eloxatin (oxaliplatin), 5-FU, and leucovorin (FOLFOX) plus xaliproden were nearly 40% less likely ... MedPage Today … - 72 FR 65968 Determination That ELOXATIN (Oxaliplatin for... - Nov 26, 2007 The agency has determined that ELOXATIN (oxaliplatin for injection), ... Accordingly, the agency will continue to list ELOXATIN (oxaliplatin for injection), ... Pay-Per-View - Federal Register 2007 - Loislaw Colorectal Cancer; Benefit of Eloxatin-based chemo plus bevacizumab... - Feb 28, 2005 2005 FEB 28 - (NewsRx.com & NewsRx.net) -- Sanofi-aventis (SNY) announced preliminary results of 2 large prospective trials evaluating the safety and ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Sanofi-aventis; Benefit of Eloxatin-based chemo plus bevacizumab for ... - Mar 2, 2005 2005 MAR 2 - (NewsRx.com & NewsRx.net) -- Sanofi-aventis (SNY) announced preliminary results of 2 large prospective trials evaluating the safety and ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Eloxatin combination reduces bowel cancer recurrences - Oct 31, 2005 Bowel cancer is one of the most common cancers occurring in humans. A clinical study involving patients taking supplementation of Eloxatin drug with other ... MedIndia FDA approves second-line bevacizumab plus chemo for metastatic … - Jul 1, 2006 The study showed that patients who received bevacizumab plus the 5-FU-based chemotherapy regimen FOLFOX4 (oxaliplatin, Eloxatin, Sanofi Aventis, ... HemOncToday Eloxatin.(NEW PACKAGING)(Brief article) - Oct 8, 2007 Sanofi-aventis Group, Bridgewater, NJ, (908) 243-6000, has introduced a new, 200-mg single-use vial of the chemotherapy agent Eloxatin (oxaliplatin ... Free with registration - Drug Topics - AccessMyLibrary.com Eloxatin and Campto gain new NICE approval - Apr 13, 2005 NICE has recommended two more chemotherapy drugs for the first-line treatment of advanced colorectal cancer. The institute said that Sanofi-Aventis' ... Pharmafocus Press Release: New Eloxatin(R) (oxaliplatin injection) Prescribing … - May 28, 2008 New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the US Includes Six-Year Overall Survival Data. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Colon Cancer; Research in colorectal cancer presented at symposium - Feb 25, 2005 An ELOXATIN-based study featured included Oxaliplatin/5FU/LV in the adjuvant ... In Europe ELOXATIN received approval in France for the second-line ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Gentler Oral Chemotherapy Shows Efficacy in Advanced Colon Cancer - Jun 29, 2005 Discuss risks and benefits of both Xeloda and Eloxatin-based adjuvant regimens. Point out that the accompanying editorial suggests that current evidence ... MedPage Today UK Watchdog Backs Wider Use of Sanofi's Eloxatin - Apr 5, 2005 LONDON APR 05, 2005 (Reuters) - Britain's cost-effectiveness watchdog NICE has backed the wider use of previously restricted colorectal cancer treatments, ... Cancerpage.com Press Release: FOLFOX4 (Eloxatin(R)-based Chemotherapy) After … - Jun 3, 2007 FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Receives FDA Approval for New ELOXATIN(TM) Formulation. - PR … - Feb 3, 2005 ...sanofi-aventis Receives FDA Approval for New ELOXATIN(TM) Formulation. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Ovarian Cancer: Platinum-Based Therapy Still the Gold Standard - Sep 11, 2006 Given the proven efficacy of cisplatin and paclitaxel, there may be potential for other platinum drugs such as Sanofi-Aventis's Eloxatin (oxaliplatin) for ... RedOrbit UK NICE widens Eloxatin, Campto use; warns of appraisals backlog due ... - Aug 29, 2005 The National Institute for Health and Clinical Excellence has updated its guidance to the National Health Service in England and Wales on the use of three ... $4.95 - Pharma Marketletter - ECNext … Marketing Approval for a New Formulation of Eloxatin(R) (Oxaliplati... - Feb 7, 2005 Eloxatin(R) was developed in association with sanofi-aventis and is currently ... Article: FDA Grants Priority Review to ELOXATIN(R) for the 1st Line ... ... Pay-Per-View - PR Newswire - HighBeam Research … solution formulation of oxaliplatin (Eloxatin, Sanofi-Aventis).(FDA... - Mar 1, 2005 A new aqueous solution formulation of oxaliplatin (Eloxatin, Sanofi-Aventis) was approved for the treatment of colorectal cancer. Free with registration - Formulary - AccessMyLibrary.com Eloxatin.(FDA Actions in brief) - Jan 1, 2005 FDA approved an expanded indicatoin for oxaliplatin (Eloxatin, Sanofi-Aventis) to include use in combination with infusional 5-fluorouracil/leucovorin for ... Free with registration - Managed Healthcare Executive - AccessMyLibrary.com FDA Approvals: Doxil, Lower-Dose Duragesic, Eloxatin - Feb 10, 2005 Feb. 10, 2005 — The US Food and Drug Administration (FDA) has approved a revised indication for doxorubicin HCl liposome injection, allowing its use in ... Medscape … of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin... - Feb 20, 2008 Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review. from PR Newswire ... Pay-Per-View - PR Newswire - HighBeam Research Japan's cancer refugees.(COMMENTARY) - Feb 23, 2007 The colorectal cancer drug Eloxatin, which was approved in America in August 2002, only made it to Japan when desperate patients-turned-activists staged ... $4.95 - Washington Times - ECNext … Release: Barr Confirms Patent Challenge of Eloxatin(R) Injectable,... - Jan 9, 2008 Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Perioperative Eloxatin(R)-Based Regimen Significantly ... - Mar 20, 2008 Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially ... Pay-Per-View - PR Newswire - HighBeam Research Sanofi-Aventis sees 9% rise in third-quarter profit, beating forecasts... - Nov 5, 2007 Within the pharmaceutical sector, three-month sales of Sanofi-Aventis' 15 leading products (excluding Eloxatin and Ambien) rose 10.8% to 3.99 billion euros ... Free with registration - Pharma Marketletter - AccessMyLibrary.com NCCN: New Guidelines Update Adjuvant Colon Cancer Treatment - Mar 21, 2005 Paul Engstrom, MD, of the Fox Chase Cancer Center in Philadelphia, chairman of the colon panel, said the addition of Eloxatin was associated with a 24% ... MedPage Today SMC approves Eloxatin and Fosavance - Dec 8, 2005 The Scottish Medicines Consortium has approved Eloxatin (oxaliplatin) for use in treating early colon cancer and Fosavance a once-weekly bisphosphonate and ... Pay-Per-View - Community Pharmacy - Factiva, from Dow Jones Press Release: The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly ... - Jun 4, 2007 The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable ... Pay-Per-View - PR Newswire - HighBeam Research … : Sanofi-aventis Announces Results of Eloxatin and Cardinal Health... - Feb 4, 2005 Sanofi-aventis Announces Results of Eloxatin and Cardinal Health to Present at Merrill Lynch Conference. from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Eloxatin. - Oct 8, 2007 Eloxatin is indicated for patients with adjuvant stage III colon cancer and advanced colorectal cancer. The new size is expected to provide greater ... $9.94 - Drug Topics - Alacra Store … -aventis announces positive trials for Eloxatin and Aastrom... - Feb 2, 2005 Sanofi-aventis announces positive trials for Eloxatin and Aastrom announces recent miles stone bone grafting trials. from M2 Presswire. Pay-Per-View - M2 Presswire - HighBeam Research Blockbuster drug sales lift Sanofi-Aventis profit. - Nov 8, 2005 Eloxatin sales rose 28 percent to A422 million (US$499 million), while Plavix revenue increased 23 percent to A534 million (US$631 million). ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Debiopharm receives US approval for injectable Eloxatin.(Brief... - Feb 14, 2005 Swiss drugmaker Debiopharm SA, has received marketing approval from the US Food and Drug Administration for its new injection formulation of the anticancer ... $4.95 - Pharma Marketletter - ECNext A new aqueous solution formulation of oxaliplatin (Eloxatin, Sanofi- … - Mar 1, 2005 A new aqueous solution formulation of oxaliplatin (Eloxatin, Sanofi-Aventis). A new aqueous solution formulation of oxaliplatin (Eloxatin, Sanofi-Aventis) ... $9.94 - Formulary - Alacra Store Press Release: New Eloxatin(R) (oxaliplatin for injection) Research... - Jan 26, 2005 The sanofi-aventis Group announced today that important data from four Eloxatin(R) (oxaliplatin for injection)-related studies will be presented at the ... Pay-Per-View - PR Newswire - HighBeam Research Establishing First-line Therapy Use is the Biggest Challenge Facing … - May 25, 2005 Several factors accounted for the preferential use of Eloxatin over Camptosar ... This data drove revenues for Eloxatin making it the market leader despite ... $4.95 - Business Wire - ECNext Sanofi-aventis Announces Results of Eloxatin and Cardinal Health to … - Feb 4, 2005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Sanofi-aventis (NYSE: SNY) announced preliminary results of ... $4.95 - M2 Presswire - ECNext ASCO GI: When Oncologists Say Risk, Patients Hear Benefit - Jan 22, 2007 By contrast, of patients who received Eloxatin (oxaliplatin)-based regimens, 46% said that numbness in the fingers and toes was worse than they expected and ... MedPage Today J&J's Profit Rises 8.9%, Led by Medical Devices - Jul 20, 2005 ...boosted by strong sales of its antistroke drug Plavix, diabetes drug Lantus and cancer drug Eloxatin. In the first half, sales of its biggest drug, ... Subscription - Wall Street Journal Online - Dow Jones & Company Trial Seeks 'Genetic Fingerprint' For Predicting Drug Effectiveness - Oct 8, 2007 Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL'-ih-plah-tin, marketed as Eloxatin) for six to eight weeks. ... sciencedaily.com Sanofi-Aventis' new form of Eloxatin approved.(Sanofi-Aventis... - Feb 14, 2005 French drugmaker Sanofi-Aventis has received clearance from the US Food and Drug Administration to market a new aqueous solution formulation of its cancer ... $4.95 - Pharma Marketletter - ECNext … -aventis announces positive trials for Eloxatin and Aastrom... - Feb 2, 2005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Sanofi-aventis (NYSE: SNY) announced preliminary results of ... $4.95 - M2 Presswire - ECNext Data to be Presented at ASCO 2007 Highlights sanofi-aventis … - May 29, 2007 Of the abstracts which have been accepted, 129 focus on Eloxatin(R), ... One hundred and ninety three Eloxatin(R) and Taxotere(R) abstracts were also ... Free with registration - PR Newswire - AccessMyLibrary.com The Colorectal Drug Pipeline Update 2007 Lists All Drugs and Gives... - Aug 27, 2007 Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as ... Free with registration - Business Wire - AccessMyLibrary.com Sanofi plans share buyback as profits fall - Aug 2, 2007 Sales of Ambien/Stilnox and Eloxatin fell thanks to new generic competition. An FDA advisory panel's thumbs down on Zimulti/Acomplia also hurt. ... FiercePharma Press Release: Data to be Presented at ASCO 2007 Highlights sanofi- … - May 29, 2007 Of the abstracts which have been accepted, 129 focus on Eloxatin(R), ... One hundred and ninety three Eloxatin(R) and Taxotere(R) abstracts were also ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: Eloxatin is also known by the following brand names and/or synonymsDACPLAT; ELOXATIN; Eloxatin; OXALIPLATIN; Oxalatoplatin; Oxalatoplatinum; Oxaliplatin [Usan:Inn:Ban]; Oxaliplatino [Spanish]; Oxaliplatinum [Latin]; Oxaloplatine [French]; Oxaloplatino [Spanish] Drug Category: Eloxatin is categorized under the following by the FDA: Antineoplastic Agents; ATC:L01XA03 Dosage Forms: Not Available Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: ethanedioate;platinum(+4)cation;(2-azanidylcyclohexyl)azanide |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |